ArticleCell stem cell2017
Engineered Epidermal Progenitor Cells Can Correct Diet-Induced Obesity and Diabetes.
Article in Cell stem cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Charting Endocrine Progenitors Across Species and Organs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advancements in CRISPR/Cas systems for disease treatment.Acta pharmaceutica Sinica. B · 2025Review
- VAMP2 controls murine epidermal differentiation and carcinogenesis by regulation of nucleophagy.Developmental cell · 2024Article
- Minimizing endogenous cryptic plasmids to construct antibiotic-free expression systems forSynthetic and systems biotechnology · 2024Article
- New medications development for smoking cessation.Addiction neuroscience · 2023Article
- Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus.Biotechnology letters · 2022Review
- CRISPR-Cas9‒Based Genomic Engineering in Keratinocytes: From Technology to Application.JID innovations : skin science from molecules to population health · 2022Review
- Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.Biotechnology letters · 2022Review
- Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platform.Molecular psychiatry · 2021Article
- Research Techniques Made Simple: Delivery of the CRISPR/Cas9 Components into Epidermal Cells.The Journal of investigative dermatology · 2021Article
- NThe EMBO journal · 2021Article
- A pulsatile release platform based on photo-induced imine-crosslinking hydrogel promotes scarless wound healing.Nature communications · 2021Article
- Regenerative Engineering: Current Applications and Future Perspectives.Frontiers in surgery · 2021Review
- A Genetically Modified Skin Graft for Treating Alcohol Use Disorder and/or Polysubstance Abuse With Cocaine.Advances in drug and alcohol research · 2021Review
- Genome-edited skin epidermal stem cells protect mice from cocaine-seeking behaviour and cocaine overdose.Nature biomedical engineering · 2019Article
- Era of Genomic Medicine: A Narrative Review on CRISPR Technology as a Potential Therapeutic Tool for Human Diseases.BioMed research international · 2019Review
- Gene surgery: Potential applications for human diseases.EXCLI journal · 2019Review
- Change the genes to fix the skin.Nature · 2018Article
- Biologically relevant laminin as chemically defined and fully human platform for human epidermal keratinocyte culture.Nature communications · 2018Article
- CRISPR/Cas9-Mediated Treatment Ameliorates the Phenotype of the Epidermolytic Palmoplantar Keratoderma-like Mouse.Molecular therapy. Nucleic acids · 2018Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Somatic gene therapy is a promising approach for treating otherwise terminal or debilitating diseases. The human skin is a promising conduit for genetic engineering, as it is the largest and most accessible organ, epidermal autografts and tissue-engineered skin equivalents have been successfully deployed in clinical applications, and skin epidermal stem/progenitor cells for generating such grafts are easy to obtain and expand in vitro. Here, we develop skin grafts from mouse and human epidermal progenitors that were engineered by CRISPR-mediated genome editing to controllably release GLP-1 (glucagon-like peptide 1), a critical incretin that regulates blood glucose homeostasis. GLP-1 induction from engineered mouse cells grafted onto immunocompetent hosts increased insulin secretion and reversed high-fat-diet-induced weight gain and insulin resistance. Taken together, these results highlight the clinical potential of developing long-lasting, safe, and versatile gene therapy approaches based on engineering epidermal progenitor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.